French biotech Generare speeds up hunt for new drugs by cloning natural molecules | TechCrunch
Generare raised €5 million to enhance its scalable methods for discovering natural compounds for drug development.
Aqemia raises $38M to find new drugs by meshing theoretical physics with GenAI | TechCrunch
Aqemia combines quantum-inspired physics and machine learning to innovate drug discovery, focusing on oncology and using synthetic data for predictions.
PhoreMost $12M Series B Financing to Advance Next-Gen Degrader Programs
PhoreMost has raised $12 million in Series B funding, advancing its pipeline for oncology and inflammatory diseases.
The company aims to move cancer treatment programs into preclinical development with this new funding.
UK-based Exciting Instruments raises 4.7M in Seed funding
Exciting Instruments raised £4M to enhance single-molecule detection technology, aiming for broader access in research and clinical applications.
French biotech firm Generare secures 5M - Silicon Canals
Generare secures €5M funding to enhance biotechnology for drug discovery by leveraging microbial DNA.
French biotech Generare speeds up hunt for new drugs by cloning natural molecules | TechCrunch
Generare raised €5 million to enhance its scalable methods for discovering natural compounds for drug development.
Aqemia raises $38M to find new drugs by meshing theoretical physics with GenAI | TechCrunch
Aqemia combines quantum-inspired physics and machine learning to innovate drug discovery, focusing on oncology and using synthetic data for predictions.
PhoreMost $12M Series B Financing to Advance Next-Gen Degrader Programs
PhoreMost has raised $12 million in Series B funding, advancing its pipeline for oncology and inflammatory diseases.
The company aims to move cancer treatment programs into preclinical development with this new funding.
UK-based Exciting Instruments raises 4.7M in Seed funding
Exciting Instruments raised £4M to enhance single-molecule detection technology, aiming for broader access in research and clinical applications.
French biotech firm Generare secures 5M - Silicon Canals
Generare secures €5M funding to enhance biotechnology for drug discovery by leveraging microbial DNA.
The startup that wants to cure diseases and slow aging, with the help of AI | Semafor
Insilico Medicine used artificial intelligence to discover a potential new treatment for idiopathic pulmonary fibrosis.
Insilico's CEO believes that AI has the potential to create hyper-targeted drugs and extend human life by inhibiting cells associated with aging.
AI Model Predicts Dual Target Drugs
AI is transforming biotechnology and pharmaceuticals by enabling the design of drugs that target multiple diseases simultaneously.
Using AI to repurpose existing drugs for treatment of rare diseases - Harvard Gazette
An AI tool called TxGNN can identify drug candidates for over 17,000 rare diseases, potentially addressing many previously untreated conditions.
Google Unveils A.I. for Predicting Behavior of Human Molecules
Artificial intelligence like AlphaFold accelerates protein understanding, drug discovery, and disease research.
Medtech startup brings Oracle AI to bear on cancer drug research | Computer Weekly
AI-driven drug discovery is poised to revolutionize cancer treatment, promising new opportunities for oncologists to improve patient care.
Google Makes New Quantum Computing Breakthrough
Google's new quantum computer shows promise for a future beyond traditional supercomputers, enhancing fields like drug discovery and artificial intelligence.
The startup that wants to cure diseases and slow aging, with the help of AI | Semafor
Insilico Medicine used artificial intelligence to discover a potential new treatment for idiopathic pulmonary fibrosis.
Insilico's CEO believes that AI has the potential to create hyper-targeted drugs and extend human life by inhibiting cells associated with aging.
AI Model Predicts Dual Target Drugs
AI is transforming biotechnology and pharmaceuticals by enabling the design of drugs that target multiple diseases simultaneously.
Using AI to repurpose existing drugs for treatment of rare diseases - Harvard Gazette
An AI tool called TxGNN can identify drug candidates for over 17,000 rare diseases, potentially addressing many previously untreated conditions.
Google Unveils A.I. for Predicting Behavior of Human Molecules
Artificial intelligence like AlphaFold accelerates protein understanding, drug discovery, and disease research.
Medtech startup brings Oracle AI to bear on cancer drug research | Computer Weekly
AI-driven drug discovery is poised to revolutionize cancer treatment, promising new opportunities for oncologists to improve patient care.
Google Makes New Quantum Computing Breakthrough
Google's new quantum computer shows promise for a future beyond traditional supercomputers, enhancing fields like drug discovery and artificial intelligence.
CEO of pharma giant Sanofi says businesses should stop 'AI washing'
AI in healthcare has enormous potential, yet there is a trend of exaggeration by executives about its current capabilities.
Heart disease is the world's biggest killer - this Cambridge Uni spinout is using AI to find new treatments | TechCrunch
AI is transforming drug discovery, particularly for cardiovascular diseases.
CardiaTec raised $6.5 million to enhance cardiovascular disease treatments through AI.
CVDs cause 17.9 million deaths annually, highlighting a major health crisis.
Orakl Oncology combines data and biology to bring new drugs to cancer patients | TechCrunch
Cancer incidence is increasing among younger adults, yet new drug trials often fail, highlighting the need for improved trial designs.
Bloomberg
1. AI is playing a crucial role in the fight against the COVID-19 pandemic, helping to analyze large amounts of data and develop solutions.
2. DeepMind's AlphaFold has shown promising results in predicting protein structures, a key step in understanding diseases and developing targeted therapies.
Cambridge startup analyses 'multi-omics' data to discover new heart drugs
CardiaTec raises $6.5mn to enhance drug discovery for cardiovascular diseases using AI-driven multi-omics data analysis.
Bloomberg
Companies are using artificial intelligence (AI) to find new drugs and treatments for diseases.
Google's DeepMind is partnering with EMBL in Germany to use AI to identify proteins that cause diseases.
CEO of pharma giant Sanofi says businesses should stop 'AI washing'
AI in healthcare has enormous potential, yet there is a trend of exaggeration by executives about its current capabilities.
Heart disease is the world's biggest killer - this Cambridge Uni spinout is using AI to find new treatments | TechCrunch
AI is transforming drug discovery, particularly for cardiovascular diseases.
CardiaTec raised $6.5 million to enhance cardiovascular disease treatments through AI.
CVDs cause 17.9 million deaths annually, highlighting a major health crisis.
Orakl Oncology combines data and biology to bring new drugs to cancer patients | TechCrunch
Cancer incidence is increasing among younger adults, yet new drug trials often fail, highlighting the need for improved trial designs.
Bloomberg
1. AI is playing a crucial role in the fight against the COVID-19 pandemic, helping to analyze large amounts of data and develop solutions.
2. DeepMind's AlphaFold has shown promising results in predicting protein structures, a key step in understanding diseases and developing targeted therapies.
Cambridge startup analyses 'multi-omics' data to discover new heart drugs
CardiaTec raises $6.5mn to enhance drug discovery for cardiovascular diseases using AI-driven multi-omics data analysis.
Bloomberg
Companies are using artificial intelligence (AI) to find new drugs and treatments for diseases.
Google's DeepMind is partnering with EMBL in Germany to use AI to identify proteins that cause diseases.
Photochemical permutation of thiazoles, isothiazoles and other azoles
The article discusses a new synthetic method using photochemical irradiation to modify thiazoles and isothiazoles, enhancing drug discovery capabilities.
Marie Curie Office Building / Proof of the Sum
Pivot Park is a hub for open innovation in drug discovery, fostering collaboration and development in the pharmaceutical field.
Generative AI: Powering the next era of life sciences innovations
Generative AI in life sciences landscape is poised to drive innovation, offering solutions for drug discovery, clinical trials, and manufacturing processes.
Generative AI will be designing new drugs all on its own in the near future
AI-driven molecule design can lead to novel drug candidates outside human imagination, pushing boundaries in medicine development.
Generative AI: Powering the next era of life sciences innovations
Generative AI in life sciences landscape is poised to drive innovation, offering solutions for drug discovery, clinical trials, and manufacturing processes.
Generative AI will be designing new drugs all on its own in the near future
AI-driven molecule design can lead to novel drug candidates outside human imagination, pushing boundaries in medicine development.
The enigma of the rare genetic mutation that protects against cancer and heart attacks
Genetic mutation in Ecuadorian families with Laron Syndrome protects from cardiovascular diseases, potential for drug discovery for aging-related diseases.
AI Is Transforming Drug Matching for Cancer, Rare Diseases | Entrepreneur
AI tools are revolutionizing drug discovery for rare diseases by repurposing existing medications, leading to cost-effective and efficient screening processes.
Refining the impact of genetic evidence on clinical success - Nature
Human genetics is crucial in identifying potential drug targets but faces challenges in application to drug discovery.
ADMET-AI: A machine learning ADMET platform for evaluation of large-scale chemical libraries
ADMET-AI is a machine learning platform predicting drug properties like absorption, distribution, metabolism, excretion, and toxicity.
Chemprop-RDKit uses a hybrid architecture to predict molecular properties, combining graph neural networks with feed-forward neural network layers.
EvolutionaryScale, backed by Amazon and Nvidia, raises $142M for protein-generating AI | TechCrunch
EvolutionaryScale raised $142 million to build AI models for creating novel proteins in scientific research.
The foundation behind Ozempic maker Novo Nordisk is funding an Nvidia-backed AI supercomputer project
Novo Nordisk is investing in an AI supercomputer through collaboration with Nvidia for drug discovery and other scientific advancements.
The Novo Nordisk Foundation's investment in the AI supercomputer is aimed at accelerating groundbreaking scientific discoveries and fostering collaboration between academia and industry.
EvolutionaryScale, backed by Amazon and Nvidia, raises $142M for protein-generating AI | TechCrunch
EvolutionaryScale raised $142 million to build AI models for creating novel proteins in scientific research.
The foundation behind Ozempic maker Novo Nordisk is funding an Nvidia-backed AI supercomputer project
Novo Nordisk is investing in an AI supercomputer through collaboration with Nvidia for drug discovery and other scientific advancements.
The Novo Nordisk Foundation's investment in the AI supercomputer is aimed at accelerating groundbreaking scientific discoveries and fostering collaboration between academia and industry.
These Companies are Changing Biotech & Biopharma with AI in 2024
AI is revolutionizing the BioTech & BioPharma space by accelerating drug discovery and development processes.
Companies like Insilico Medicine and Exscientia are using AI platforms to design and optimize drug candidates, leading to faster timelines and more efficient drug development.
Karim Beguir Wants to Empower the World With AI
InstaDeep, a decision-making AI company, has challenged the tech status quo by setting up shop in Tunis and operating in the complex domain of deep tech.
The company builds AI systems that can make decisions for businesses, with applications ranging from drug discovery to energy efficiency.
Podcast: AI-Enabled Drug Discovery with Daphne Koller
Daphne Koller discusses AI's role in biotechnology, specifically drug discovery.
The importance of high-quality data and ethical considerations in using AI for biotechnology.
Bloomberg
Google's AI research lab, DeepMind, has developed a new algorithm for generating computer programs.
The algorithm, called AlphaFold, uses deep learning to predict the 3D structure of proteins.
AI Program Finds Thousands of Possible Psychedelics. Will They Lead to New Drugs?
AlphaFold, an AI tool developed by DeepMind, has been used to identify new potential psychedelic molecules for developing antidepressants.
AlphaFold predictions can be just as useful for drug discovery as experimentally derived protein structures.
'Supermodel granny' drug extends life in animals
A drug increased lab animals' lifespan by 25% with potential for human aging; impact on inflammation control identified.
Sick chimpanzees self-medicate using plants with medicinal properties
Chimpanzees in Uganda self-medicate with medicinal plants rich in antibacterial and anti-inflammatory properties, suggesting a potential for discovering new drugs through studying their behavior.